Hospital

The indication is for the reduction of proteinuria in adult patients who have primary immunoglobulin A nephropathy and are at risk of disease progression.

Significant commonalities between type 2 diabetes and neurodegenerative disorders suggest that treatments effective for one condition may benefit the other.

Acalabrutinib plus venetoclax, with or without obinutuzumab, demonstrated significant improvements in progression-free survival.

CD38 density may indicate the efficacy of monoclonal antibody treatment in patients with multiple myeloma.

Sunobinop binds to and activate nociception/orphanin-FQ peptide receptor, which is a known therapeutic target for substance use disorder.

A report from SkyQuest Technology highlights the growth in the oncology and insulin spaces, indicating they will contribute to the most growth.

The drug also receives orphan drug designation for the treatment of pancreatic neuroendocrine tumors and a Prescription Drug User Fee Act target action date of April 3, 2025.

Two different brands of intravenous immunoglobulin have been investigated, finding Brand P led to significantly longer durations of fever and hospitalization when compared to brand T.

The mRNA-1345 vaccine provides a one-off mechanism of protection because of its single-dose prefilled syringes

The findings highlight the potential for developing more efficacious combination treatments for patients with glioblastoma.

Zuranolone enhances health care providers’ ability to address the complex needs of patients with PPD, offering new hope for rapid and sustained relief from depressive symptoms.

The findings show that inhibiting connexin 43 significantly improves multiple sclerosis symptoms in an experimental mouse model.

Afamitresgene autoleucel (afami-cel) is a novel cell therapy for the treatment of patients with synovial sarcoma.

Dolutegravir/lamivudine was non-inferior to bictegravir/emtricitabine/tenofovir alafenamide fumarate, meeting the study’s primary end point.

The experimental drug successfully reduced levels of SIV, the nonhuman primate equivalent of HIV, in the brain.

Afami-cel was approved in conjunction with MAGE-A4 IHC 1F9 pharmDx, a diagnostic tool that can identify patients eligible to receive the treatment for synovial sarcoma.

The diagnostic tool can aid the identification of patients with synovial sarcoma who may be eligible for treatment with newly approved afamitresgene autoleucel.

This is the first and only on-demand, virus-inactivated, human plasma-derived concentration option that is indicated for this approval.

Pharmacists play a key role in the use of live biotherapeutic products, including fecal microbiota, live-jslm for prevention of recurrent Clostridioides difficile (C difficile) infection.

Fabry disease is a rare X-linked, lysosomal storage disorder that can cause renal failure or stroke.

The findings provide guidance for clinicians and patients when navigating therapeutic options to establish treatment plans.

Understanding and accounting for linguistic diversity is critical in diagnostics and treatment for dementia.

Pharmacies can adapt by embracing digital self-service options to better engage with patients, meet increasing consumer demand, and enhance revenue streams.

If approved, the drug would be the first in a new class of medications to treat acute pain in over 20 years.

The approval streamlines treatment administration to eliminate compounding steps, reduce preparation time, and enhance safety for clinicians.

By functioning as an antibody replacement therapy, IVIG can be used to manage a wide range of inflammatory and autoimmune disorders.

Educate patients about the importance of vaccination in preventing severe disease.

One-third of patients treated with deuruxolitinib displayed 80% of scalp hair coverage.

Early identification of monoclonal gammopathy of undetermined significance leads to more efficacious disease monitoring and intervention.

Advancements in treatment include immune checkpoint inhibitors and BRAF/MEK inhibitors, though resistance remains a challenge, with lifileucel recently approved for previously treated metastatic cases.